Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma Daniel Huang NUS vist.ly/x5fh #livercancer news #livercancer #liverdisease #researchstudy

What is the natural history of MASLD?

What is the median survival after a first decompensating episode?

This study MASLD Research Center provides some answers Rohit Loomba Nabil Noureddin Alina Allen Veeral Ajmera roypounder.apt

onlinelibrary.wiley.com/doi/10.1111/ap…

Arun J. Sanyal awed us with intrapatient reliability in MR so, important to note these agreement/reliability measures in human science [aka clinimetrics]
gut.bmj.com/content/64/7/1… Gut Journal

Today’s #readoftheweek 📚 highlights the increased prevalence of ALD in the elderly, with a burden of AUD comparable with that in the overall population.

Read here this 🔓 #openaccess JHEP Reports article: jhep-reports.eu/article/S2589-…

🙏 @pojsakorndan, @karnjuve, Juan Pablo (JP) Arab, MD ,…

Our #ImplementationScience study on #MobileTechnology based #LifestyleIntervention in #MASLD published in Scientific Reports
rdcu.be/dCPes
💠real world implementation results less robust on metabolic & hepatic outcomes
💠⬇️Age & #diabetes correlated with unhealthy diet

Here is the summary of new eligibility criteria for treatment of #HBV from the new ⁦World Health Organization (WHO)⁩ guidelines. HBV >2000 and ALT >ULN will encompass most of patients in our clinics. IMO patient choice still critical. ⁦Hep B Foundation⁩ ⁦British Liver Trust⁩ ⁦ICE-HBV⁩

Congratulations to Dr Rashid Lui 雷諾信 on being named as the Top 100 #Xfluencers in #ColorectalCancer by OncoDaily!

#ColorectalCancer AwarenessMonth #Xfluencers 2024

#LiverTwitter Successful inaugural meeting with international friends marking the start of #ProjectLiveWISER ! 😍 Grateful to Prof Takahashi, Prof Holden, Daniel Huang, Prof Sak, Prof Morishita, Apichart P. Margaret LP Teng Benjamin Nah Nicholas Syn (missing Prof Noritake and Prof Zheng)

🚨Check out our paper in Mayo Clinic Proceedings
📈 Mortality from MASLD, DM, and Obesity is increasing in #premenopausal women
📈 Obesity is projected to increase by 42% from 2019 to 2040
Karn Wijarnpreecha Cheng Han Ng Mazen Noureddin, MD, MHSc Daniel Huang

There are various definitions of ACLF but a clear & standardised definition is lacking. Here we propose steps for harmonisation. EASLnews EASL Education AASLD The Baveno Cooperation: an EASL Consortium AARC_APASL APASL News Paolo Angeli Shiv Sarin Journal of Hepatology #livertwitter
journal-of-hepatology.eu/article/S0168-…

So pumped up to work along Eur. Fdn. for the Study of Chronic Liver Failure Jonel Trebicka vice-secretary EASLnews Debbie Shawcross and Alexander Gerbes about novel therapies and approaches to tackle #aclf . We highlighted U.S. FDA BEST framework to tackle future biomarker development in ACLF ncbi.nlm.nih.gov/books/NBK32679…

Nothing like a medication approval for non cirrhotic #MASH with fibrosis to stimulate discussion and education about NITs. Ultimately patients benefit and we all learn Naim Alkhouri Mazen Noureddin, MD, MHSc Daniel Huang Rohit Loomba Yaron Rotman #rezdiffra #livertwitter

Non-invasive tests are proving to be as good as, if not better than, liver biopsy in predicting patient prognosis for steatotic liver disease. #LiverDisease #MedicalResearch doi: 10.1001/jama.2024.1447

The #MASH Resolution Index presents a promising tool for non-invasively pinpointing MASH resolution, potentially serving as a crucial endpoint in Phase 2a trials to boost the chances of Phase 2b trial success. Dive into the full details of this pioneering…

Today, FDA approved a medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. fda.gov/news-events/pr…

Resmetirom approved for Rx of NASH related fibrosis- 1st FDA approved Rx for one of the biggest untapped therapeutic areas by Madrigal Pharmaceuticals !!! AASLD American Gastroenterological Association (AGA)
Madrigal granted FDA approval for NASH therapy msn.com/en-us/health/o…

#AATLD ⁦Raj VuppaLanchi⁩ - talking about VCTE, MRE, ELF, ProC3 in AATLD ⁦Indiana University Gastroenterology and Hepatology⁩ ⁦UCSD Gastroenterology⁩ ⁦Veeral Ajmera⁩ ⁦Daniel Huang⁩ ⁦Monica Tincopa MD MSc⁩ ⁦Focusmed24⁩

Amazing energy in the room and great engagement by stakeholders UC San Diego Health Sciences @UCSDHealth Christopher A. Longhurst Patty Maysent Daniel Huang

The growing threat of non-alcoholic fatty liver disease-related hepatocellular carcinoma hbsn.amegroups.org/article/view/1…